Important Announcements - Company Shouwei New Materials will suspend trading for inspection on July 31, 2025, due to abnormal stock price fluctuations from July 9 to July 30, 2025 [2] - Company XGIMI Technology expects a net profit attributable to shareholders of 88.66 million yuan for the first half of the year, a year-on-year increase of 2062.33% [4] - Company Yuntian Lifei has submitted an application for H-share issuance and listing [5] - Company Huaheng Biological is planning to issue H-shares and list on the Hong Kong Stock Exchange [6] - Company Hehua Co., Ltd. is planning a change in control, leading to a suspension of trading [10] Financial Performance - Company Dingtong Technology reported a net profit of 115 million yuan for the first half of the year, a year-on-year increase of 134.06%, with a proposed cash dividend of 2 yuan per 10 shares [7] - Company Jinhai Biological achieved a net profit of 138 million yuan in the first half of the year, a year-on-year increase of 51.52% [13] - Company Hisense Home Appliances reported a net profit of 2.077 billion yuan for the first half of the year, a year-on-year increase of 3.01% [14] Corporate Actions - Company Nanxin Pharmaceutical is planning to acquire a domestic pharmaceutical technology asset group, but there is significant uncertainty regarding the completion of this acquisition [3] - Company Jinchengzi is planning to acquire 55% of the shares of Changchun Samit Optoelectronics Technology Co., Ltd., leading to a suspension of trading [9] - Company San Chao New Materials is also planning a change in control, resulting in a trading suspension [11] Project Investments - Company Changjiang Electric Power plans to invest approximately 26.6 billion yuan in the construction of the Gezhouba Navigation Capacity Expansion Project [8]

Group 1: Company Announcements - Upwind New Materials will suspend trading for stock review starting July 31, 2025, due to abnormal price fluctuations from July 9 to July 30, 2025 [2] - XGIMI Technology expects a net profit attributable to shareholders of 88.66 million yuan for the first half of 2025, a year-on-year increase of 2062.33% [4] - CloudWalk Technology has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [5] - Huaheng Biological is planning to issue H-shares and list on the Hong Kong Stock Exchange [6] - Hehua Co., Ltd. is undergoing a control change process, leading to a stock suspension starting July 31, 2025 [9] Group 2: Financial Performance - DingTong Technology reported a net profit of 115 million yuan for the first half of 2025, a year-on-year increase of 134.06%, with a proposed cash dividend of 2 yuan per 10 shares [7] - Jinhe Biological achieved a net profit of 138 million yuan in the first half of 2025, a year-on-year increase of 51.52% [12] - Hisense Home Appliances reported a net profit of 2.077 billion yuan for the first half of 2025, a year-on-year increase of 3.01% [13] Group 3: Corporate Developments - Nanxin Pharmaceutical is planning to acquire a domestic pharmaceutical technology asset group, but there is significant uncertainty regarding the completion of this acquisition [3] - Jinchengzi is planning to acquire 55% of the equity of Changchun Samit Optoelectronics Technology Co., Ltd., leading to a stock suspension starting July 31, 2025 [8] - SanChao New Materials is also planning a control change, resulting in a stock suspension starting July 31, 2025 [10] Group 4: Industry Developments - Changjiang Electric Power plans to invest approximately 26.6 billion yuan in the construction of the Gezhouba Navigation Capacity Expansion Project, with a total construction period of 91 months [8] - Yonghui Supermarket intends to raise no more than 3.992 billion yuan through a private placement to upgrade stores and logistics [8]

Core Viewpoint - Yuntian Lifei is a leading AI company in China, focusing on the research, design, and commercialization of AI inference chips, aiming to create a complete closed-loop from infrastructure to product design and commercialization [3]. Industry Overview - The AI inference chip market in China is experiencing rapid growth, with the market size projected to increase from RMB 11.3 billion in 2020 to RMB 162.6 billion by 2024, representing a compound annual growth rate (CAGR) of 94.9%. It is expected to continue growing at a CAGR of 53.4% from 2024 to 2029, reaching RMB 1,383 billion by 2029 [3]. - Yuntian Lifei ranks among the top three providers of AI inference chip products and services in China based on revenue projections for 2024 [3]. Company Products and Technology - Yuntian Lifei's IFIC platform enables algorithm chip integration, allowing the company to develop optimized chips for various applications. The company has launched NPU products such as Nova, DeepEye, DeepEdge, and is working on DeepVerse and DeepXBot [4]. - The Hy3 CAN hardware tool and IFIE software platform support the operation of AI inference chips, providing a unified programming interface and a controlled development environment for large model applications [4]. Financial Performance - For the fiscal years ending March 31, 2022, 2023, 2024, and the first quarter of 2025, Yuntian Lifei reported revenues of approximately RMB 546.2 million, RMB 506.0 million, RMB 917.4 million, and RMB 264.0 million, respectively. Corresponding gross profits were approximately RMB 174.1 million, RMB 119.0 million, RMB 192.1 million, and RMB 76.0 million [5][6]. - The company has shown a trend of increasing revenue, with a notable jump in 2024, while gross profit margins have varied, indicating potential challenges in cost management [5][6].

Company Overview - Yuntian Lifei is a leading AI company in China, focusing on the research, design, and commercialization of AI inference chips. The company integrates deep understanding of AI algorithms and practical application scenarios into high-performance, cost-effective applications, offering products and services across enterprise, consumer, and industry-level applications [4]. Industry Growth - The AI inference chip-related products and services industry in China is experiencing rapid growth, with the market size increasing from RMB 11.3 billion in 2020 to RMB 162.6 billion by 2024, representing a compound annual growth rate (CAGR) of 94.9%. It is projected to continue growing at a CAGR of 53.4% from 2024 to 2029, reaching RMB 1,383 billion by 2029 [4]. Market Position - According to a report by Zrac Consulting, Yuntian Lifei ranks among the top three providers of AI inference chip-related products and services in China based on revenue statistics for 2024. The company is also positioned as one of the top two providers specifically for NPU-driven AI inference chips [4]. Product Development - Yuntian Lifei's IFIC foundation enables algorithm chip capabilities. The company has developed NPU products such as Nova, along with AI inference chips including DeepEye and DeepEdge, and is working on products like DeepVerse and DeepXBot. The Hy3CAN hardware enabling tool and IFIE software platform support the operation of AI inference chips [5]. Financial Performance - For the fiscal years ending March 31, the company reported revenues of approximately RMB 546.2 million, RMB 506.0 million, RMB 917.4 million, and RMB 98.4 million for 2022, 2023, 2024, and the first three months of 2025, respectively. Corresponding gross profits were approximately RMB 174.1 million, RMB 118.8 million, RMB 192.1 million, and RMB 13.9 million [6][7].

Core Viewpoint - Yuntian Lifei is a leading AI company in China, focusing on the research, design, and commercialization of AI inference chips, aiming to create a complete closed loop from infrastructure to product design and commercialization [4]. Industry Overview - The AI inference chip market in China is experiencing rapid growth, with the market size projected to increase from RMB 11.3 billion in 2020 to RMB 162.6 billion by 2024, representing a compound annual growth rate (CAGR) of 94.9%. It is expected to reach RMB 1,383 billion by 2029, with a CAGR of 53.4% from 2024 to 2029 [4]. Company Positioning - Yuntian Lifei ranks among the top three providers of AI inference chip products and services in China, and is also positioned as one of the top two providers specifically for NPU-driven AI inference chips based on projected revenue for 2024 [4]. Product Development - The company has developed the IFIC platform, which enables algorithm chip capabilities, and has created several NPU products, including Nova, DeepEye, DeepEdge, and others, along with supporting hardware and software tools [5]. Financial Performance - For the fiscal years ending March 31, 2022, 2023, 2024, and the first quarter of 2025, Yuntian Lifei reported revenues of approximately RMB 546.2 million, RMB 506.0 million, RMB 917.4 million, and RMB 264.0 million, respectively. The gross profits for the same periods were approximately RMB 174.1 million, RMB 119.0 million, RMB 192.1 million, and RMB 76.0 million [6][7].

证券代码：688343 证券简称：云天励飞 公告编号：2025-047 深圳云天励飞技术股份有限公司 关于向香港联交所递交 H 股发行并上市的申请 并刊发申请资料的公告 英文：https://www1.hkexnews.hk/app/sehk/2025/107588/documents/sehk25073 000860.pdf 需要特别予以说明的是，本公告仅为境内投资者及时了解本次发行并上市的 相关信息而作出。本公告以及公司刊登于香港联交所网站的申请资料不构成也不 得视作对任何个人或实体收购、购买或认购公司本次发行上市的 H 股股票的要 约或要约邀请。 公司本次发行上市尚需取得中国证券监督管理委员会、香港证监会和香港联 交所等相关政府机关、监管机构、证券交易所的批准、核准或备案，并需综合考 虑市场情况以及其他因素方可实施，仍存在不确定性。公司将根据该事项的进展 情况及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 深圳云天励飞技术股份有限公司董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳云天励飞 ...

格隆汇7月30日丨云天励飞(688343.SH)公布，公司已于2025年7月30日向香港联合交易所有限公司(以下 简称"香港联交所")递交了发行H股股票并在香港联交所主板挂牌上市(以下简称"本次发行上市")的申 请，并于同日在香港联交所网站刊登了本次发行上市的申请资料。该申请资料为公司按照香港证券及期 货事务监察委员会(以下简称"香港证监会")及香港联交所的要求编制和刊发，为草拟版本，其所载资料 可能会适时作出更新和变动，投资者不应根据其中的资料作出任何投资决定。 ...

云天励飞公告，公司已于2025年7月30日向香港联交所递交了发行H股股票并在香港联交所主板挂牌上 市的申请，并于同日在香港联交所网站刊登了本次发行上市的申请资料。本次发行对象将仅限于符合相 关条件的境外投资者及依据中国相关法律法规有权进行境外证券投资的境内合格投资者。 ...

格隆汇7月30日｜据港交所文件，深圳云天励飞技术股份有限公司向港交所提交上市申请书。 ...

智通财经7月30日电，利弗莫尔证券显示，深圳云天励飞技术股份有限公司向港交所提交上市申请书， 联席保荐人为华泰国际、中信证券和招银国际。 ...